Development of Orphan Drugs in Japan: Characteristics of Orphan Drugs Developed in Japan

Abstract

Since 1993, some support measures to promote development of orphan drugs have been introduced. This support system was modeled after the United States system, but the contents were slightly different. The annual average numbers of orphan drug designations in Japan is about one half of those in the United States. The proportion of approved orphan drugs to designated drugs in Japan was 2.0 times of that in the United States. In the United States, 77% of applicants were smaller companies, but in Japan only 3% of applicants were venture companies. In Japan more drugs were introduced from overseas than developed in the country. Looking at the designated orphan drugs, drugs with less chance of failure which required less money for development tend to have been developed in Japan. Most of the applicants were larger companies. It seems important to view the support measures from the point of view of fostering venture companies.

This is a preview of subscription content, access via your institution.

We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

References

  1. 1.

    Hirai T, Urayama T. Intractable diseases and orphan drugs. Farumashia. 1995;31(7):770–778.

    Google Scholar 

  2. 2.

    Shulman SR, Mancocchia M. The US Orphan Drug Programme. Pharmacoeconomics. 1997:12:312–326.

    CAS  Article  Google Scholar 

  3. 3.

    Organization for Pharmaceutical Safety and Research ed. Orphan Drug Development Promotion System. Tokyo, Japan: Organization for Pharmaceutical Safety and Research; 1999.

    Google Scholar 

  4. 4.

    Morning Paper of Nihon Keizai Shimbun. February 16, 1999.

  5. 5.

    Ohtaki Y, et al. Venture business and university. EAJ Information. 1999;81:1–25.

    Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Dr. Makoto Shiragami PhD.

Additional information

The views expressed in this article are solely those of the authors, and official endorsement by the Ministry of Health and Welfare or The Organization for Pharmaceutical Safety and Research should not be inferred.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Shiragami, M., Nakai, K. Development of Orphan Drugs in Japan: Characteristics of Orphan Drugs Developed in Japan. Ther Innov Regul Sci 34, 839–846 (2000). https://doi.org/10.1177/009286150003400320

Download citation

Key Words

  • Orphan drug
  • Orphan drug designation
  • Support system for orphan drugs
  • Orphan drug applicants